<SEC-DOCUMENT>0001513162-20-000098.txt : 20200511
<SEC-HEADER>0001513162-20-000098.hdr.sgml : 20200511
<ACCEPTANCE-DATETIME>20200508213626
ACCESSION NUMBER:		0001513162-20-000098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200507
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200511
DATE AS OF CHANGE:		20200508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20862378

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>WASHINGTON, D.C.</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>FORM 8-K</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>CURRENT REPORT</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Pursuant to Section 13 or 15(d) of the</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Securities Exchange Act of 1934</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center>Date of Report (date of earliest event reported): <b>May 7, 2020</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>BIOMERICA, INC.</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Exact Name of Registrant as Specified in its Charter)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=633 bordercolor=transparent style=WIDTH:633px cellpadding=0 cellspacing=0> <tr> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Delaware</p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>001-37863</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center>95-2645573</p></td></tr> <tr> <td width=93 style="WIDTH:69.75pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=left>(State or Other Jurisdiction of Incorporation)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=83 style="WIDTH:62.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=left>(Commission File Number)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=138 style="WIDTH:103.5pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=left>(IRS Employer Identification Number)</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>17571 Von Karman Ave.</p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'>Irvine, California 92614</h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Address of Principal Executive Offices</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Zip Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>949-645-2111</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Registrant&#146;s Telephone Number,</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Area Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'><strong>Not applicable</strong></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Former Name or Former Address if Changed</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Since Last Report)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style="MARGIN:0in 0in 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="MARGIN:12pt 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="MARGIN:0in 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>1</font></p> <p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="MARGIN:0in 0in 0pt"><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style="MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%">Securities registered pursuant to Section 12(b) of the Act:</p> <div align=center> <table width=683 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:176pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:267pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:176pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:267pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font face=Wingdings><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp; <font face=Wingdings>o</font></font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font face=Wingdings><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; </font>o</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p><font face=Wingdings> <p style="MARGIN:0in 0in 0pt"><b><font face="Times New Roman">Item 7.01 Regulation FD Disclosures.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font face="Times New Roman">On May 7, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing the receipt of a CE mark for a new high-volume version of a ten-minute test for COVID-19 exposure and the expansion of its international distribution. A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p>  <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font face="Times New Roman">The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'></font>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>Item 8.01&nbsp; Other Events</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=_Hlk39847039>On May 5, 2020, Biomerica received a CE mark and launched a new high-volume production version of its COVID-19 IgG/IgM Rapid Test (the &#147;COVID-19 Test&#148;) that utilizes a proprietary card system that eliminates most plastic.&nbsp; The COVID-19 Test is a serology, finger prick blood test designed to detect antibodies in a person to indicate if that person has had an immune response to the novel Corona Virus (SARS CoV-2).&nbsp; In addition, Biomerica expanded its provisional patent applications to include new technology that is being validated to simplify blood sample collection for its high throughput ELISA test.</a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black'><strong>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</strong></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; PADDING-LEFT:0px; MARGIN:0in 0in 0pt 48px'>(d)&nbsp; Exhibits</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><strong><font style=FONT-SIZE:10pt><u>Number</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description</u></font></strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>Press Release issued May 7, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>3</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in'>SIGNATURE</h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0.3in 0pt 0in' align=right>&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black">Dated:&nbsp; May 11, 2020</font></a></p></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>4</font></p></div></body>
<!-- EDGAR Validation Code: 6CD33707 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
<META NAME="author" CONTENT="Scott Powell">
<META NAME="date" CONTENT="2020-05-08T21:10:00Z">
</HEAD>
<BODY style="margin-top:0;font-family:'Times New Roman'; font-size:10pt; color:#000000">
<P style="margin-top:0px; margin-bottom:16.733px" align=justify><img src="graphic.jpg" alt="[graphic.jpg]" align=middle></P>
<P style="margin-top:8px; margin-bottom:0px" align=justify><BR></P>
<P style="margin-top:12.733px; margin-bottom:0px; font-family:'Avenir,Times New Roman'; font-size:17.5pt; color:#002C40" align=justify><B>Biomerica </B><B>Receives CE mark for</B><B> New </B><B>High-Volume</B><B> Version of </B><B>10 Minute </B><B>Test for COVID-19</B><B> </B><B>Exposure</B><B> </B><B>and Expands International Distribution</B></P>
<P style="margin-top:0px; margin-bottom:8px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:72px; width:96px; font-family:'Courier New'; font-size:11pt; float:left">o</P>
<P style="margin-top:0px; margin-bottom:9.8px; padding-left:96px; text-indent:-2px; font-family:'Avenir,Times New Roman'; font-size:13.5pt; color:#002C40" align=justify><B>New </B><B>h</B><B>igh</B><B>-v</B><B>olume </B><B>production </B><B>test </B><B>allows Biomerica to expand </B><B>i</B><B>nternational distribution to </B><B>better </B><B>meet demand of </B><B>its </B><B>10-minute test for coronavirus exposure</B><B>. </B><B>The t</B><B>est</B><B> </B><B>can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s office</B><B> </B><B>utilizing blood from a finger prick</B><B>.</B></P>
<P style="margin-top:0px; margin-bottom:8px; clear:left" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:72px; width:96px; font-family:'Courier New'; font-size:11pt; float:left">o</P>
<P style="margin-top:0px; margin-bottom:9.8px; padding-left:96px; text-indent:-2px; font-family:'Avenir,Times New Roman'; font-size:13.5pt; color:#002C40" align=justify><B>Biomerica </B><B>also announced it </B><B>is now filling and </B><B>has shipped </B><B>commercial </B><B>orders of its previously </B><B>announced </B><B>version of the </B><B>product </B><B>to </B><B>Company distributors </B><B>who are supplying customers that include NATO, and g</B><B>o</B><B>ve</B><B>rnment agencies in Germany, </B><B>Switzerland</B><B> and</B><B> </B><B>the Netherlands</B><B>.</B></P>
<P style="margin-top:0px; margin-bottom:9.8px; clear:left"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:72px; width:96px; font-family:'Courier New'; font-size:11pt; float:left">o</P>
<P style="margin-top:0px; margin-bottom:9.8px; padding-left:96px; text-indent:-2px; font-family:'Avenir,Times New Roman'; font-size:13.5pt; color:#002C40" align=justify><B>The </B><B>suggested price point of the </B><B>new </B><B>h</B><B>igh</B><B>-v</B><B>olume </B><B>t</B><B>est maintains </B><B>at</B><B> </B><B>$10 per patient</B><B> price</B><B>.</B></P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>IRVINE, CA--(May 07, 2020) - Biomerica Inc. (NASDAQ: <FONT style="color:#0071BB">BMRA</FONT><FONT style="color:#0071BB"></FONT>) today announced it has received a CE mark and <FONT style="font-family:'Times New Roman'; font-size:11pt; color:#000000">&nbsp;</FONT>launched a new high-volume production version of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere) being sold in countries outside the US. &nbsp;This new high-volume version of the disposable serology test allows the company to ramp up production utilizing a proprietary card system that eliminates most plastic. The high-volume production version of this test is intended for larger customers doing high-volume screenings. This version also has the benefit of being environmentally friendly. </P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>The Company also is announcing it has shipped and continues to supply the previously announced cassette version of its disposable finger prick test to its distribution partners who are supplying multiple customers that include NATO, and government agencies in Germany, Switzerland and the Netherlands among others. The high-volume version of the test uses the same technology as the cassette version which has been well accepted in Europe and other countries in terms of performance. &nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify><B>Patent</B><B>s</B><B> and high-volume laboratory version test</B></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>Biomerica has also expanded its provisional patent applications to include new technology that is being validated to simplify blood sample collection for its high throughput ELISA test. &nbsp;The company expects to launch its ELISA high-volume laboratory version serology test with<FONT style="font-family:'Times New Roman'; font-size:11pt; color:#000000"> </FONT>high accuracy and low cross-reactivity in accordance with the newly released EUA guidance. &nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify><B>About </B><B>Serology Tests</B></P>
<P style="margin:0px" align=justify><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40; page-break-before:always" align=justify>Biomerica<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s rapid-test technology is a serology test. Serology tests look for the presence of antibodies, which are specific proteins made in response to infections. The antibodies detected by serology tests indicate that a person has had an immune response to the novel Corona Virus (SARS CoV-2), whether symptoms developed from infection or the infection was asymptomatic. </P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>Zackary Irani, Chairman and Chief Executive Officer, stated, <font style="font-family:'Arial Unicode MS,Times New Roman'">&#8220;</font>The devastating effects on the lives of people affected by COVID-19 continues to be problematic. &nbsp;Our existing point of care test has been well accepted in international markets and we are now expanding sales distribution to other countries. <FONT style="font-family:'Times New Roman'; font-size:11pt; color:#000000">&nbsp;</FONT>Our launch of these COVID-19 serology tests is by no means a shift in the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s stated strategy of growing both our colorectal disease detection product, finalizing clinical trials and gaining FDA approval for our HP Detect<FONT style="font-family:'Calibri,Times New Roman'"><font style="font-family:'Arial Unicode MS,Times New Roman'">&#8482;</font></FONT> <I>H. Pylori</I> test and our InFoods&#174; IBS therapy product.<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8221;</font> &nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify><B>About Biomerica (NASDAQ: </B><FONT style="color:#0071BB"><B>BMRA</B></FONT><FONT style="color:#0071BB"><B></B></FONT><B>)</B> </P>
<P style="margin:0px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>Biomerica, Inc. (<FONT style="color:#0071BB">www.biomerica.com</FONT><FONT style="color:#0071BB"></FONT>) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development. </P>
<P style="margin-top:6.333px; margin-bottom:6.333px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>The Private Securities Litigation Reform Act of 1995 provides a &quot;safe harbor&quot; for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s COVID-19 test, the rapidity of testing results, pricing of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s test kits, demand for international orders, availability of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s COVID-19 test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: &nbsp;results of studies testing the efficacy of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s COVID-19 test; regulatory approvals necessary prior to commercialization of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s COVID-19 test; availability of the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company<font style="font-family:'Arial Unicode MS,Times New Roman'">&#8217;</font>s ability to obtain patent protection on any aspects of its rapid test technology. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</P>
<P style="line-height:22.5pt; margin-top:7px; margin-bottom:7px; font-family:'Avenir,Times New Roman'; font-size:11.5pt" align=justify><B>CONTACT INFORMATION</B></P>
<P style="margin-top:6.333px; margin-bottom:6.333px; padding-left:24px; font-family:'Avenir,Times New Roman'; font-size:10.5pt; color:#002C40" align=justify>Company Spokesperson<BR>
949-645-2111<BR>
<FONT style="color:#0071BB">www.biomerica.com</FONT><FONT style="color:#0071BB"></FONT></P>
<P style="margin:6.333px" align=justify><BR>
<BR></P>
</BODY>
<!-- EDGAR Validation Code: 46FAA7C9 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  G .@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**_./\
MX+I?\%"/B%^R5XQ^'_A[X<>)#X>OM1L[K4=49;2"X::,ND< _>HX RD_3&?P
MK2^%GP"_;:^*OPIT#Q(?VAO#^DGQ#IEOJ26<N@0&6V$T2R"-R+?&X;@#C/(-
M?5T^%*GU&EF&(KTZ<*E^7FYKZ.VRBSY*IQ=2^OU<NP]"I5G2MS<JC;5)[RDC
M]"J*_&GXA?\ !3G]J/\ 8+_:P;P#X_\ $GA[XAG3I[;[1:QV$ 2^AF577RY(
MXHI$D*,,!APV/E8=>B_X*<?\%./C3X&_;^U+X<_"WQ=+I%A9G3]+BLX]/M9_
M-O9HXW;YI(F;.Z94QG'RUZ-/P\S"I6A2A4@XS@YJ5WR\JY?[M_M+H>94\1\N
MIT*E6I3J*4)J#C9<W,^;^];[+ZGZZ45^6?[7W_!8KXE2_'JU^"7P+MK76/$E
MA<QZ!=>()[5+BXU744_=R^1&<0H@<-EW4CAB JC)]4\._L/?MD>)='AO/$'[
M3]OHVJ2J))+.PT=)X821G;O"Q XZ'"X^M<$^$JF'HPK8^O"CSJ\5+F<FN]HQ
M=EZGH4^,*6)K3HY?0J5N1VDX\JBGVO*23?I^1]\45^/?[3/[:7[6W_!+;XRZ
M1I7C;QMH7Q#T75H?MED]Q81&WOXD8+(A94CFCD7(R-Q W*<M7?\ _!37_@K5
MXUTCX:?!"Z^$6I7/AG5OB)I!U^]MQ:P7<Z)(4BA@ D1@?WHG&0!NV"NJ/ 6/
MJ5**H3A.%:_+--\NB;=]+K9]-]#DEX@Y?3IUW7A.$Z-N:#2YM6DK:V>ZZ[:G
MZBT5^8__  1)_P""C7Q-_:7_ &A?%W@KXG>)9-<ECT8W^GI-96]LUO+#.J2K
M^ZC3)(E!(.?]7]:^Z/VQ/VI]!_8U_9_USQWK[!X].C\NRM VV34;MP1% GNQ
M')_A56;HIKQLTX<QF!S!9;-*51VMRZI\VUKI>A[>4\2X/'Y<\TA>--7OS637
M+O>S?J>H45^!EA_P5\_:F\;^-=+MK;QW/8'Q5>K'I\,>BV0B/F3F(+'NA+%%
M?* DD_*022#7NG[?/_!2CXZ:#_P4*U#X6?##QP]A96]YIWA^UB.G6DHGO9(X
M5D=F>)F&9I&!QP,<"OII^&F90KQP\JE.[C*6\K)1<4[^[_>_!GRU/Q0RR="6
M(C2J64HQM:-VY*35O>[1_%'Z_P!4-9\,:?XA0K?6D%TI&")%SQ7P6?V<?^"@
M9'_)<?AM_P" 4?\ \KZS_%D7[7'['WPG\=?$7XI_%_PMKF@^'O#=Y]AL],M8
MO,?4IE$%F[9LXQM2657QNY*@$$$UXBX8A-J%+%TI2=DDG*[;T27N'OKBRI2_
M>3PE:$5JY-1226K;M/H?;VI_LX^ M:_X^_"'AZY_ZZV2/_,5BW?[%7PBOGW3
M?#3P1*?5]'@/_LM?FE_P3N^/'[7G_!0^Y\4?V-\:[7P[:>%EMO/N+W0+.43/
M-YFU%"P=0(F)R>XKT?\ :UT+]M;]C+X.:I\0I/CIX?\ %>C:"8WO[<:+:Q3)
M&\BQAE1[?:PW.N1N!P> <5UU^"94L9]0J8JDJMTN6\]W:ROR6UNNIKA/%/&R
MP7]H8>&)]C9OF4ELMW;VE]+/H?:-Y_P3R^!=^/WOPF\!-[_V/"#^86L?4O\
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MOKU*MC/8)7YG.ZMWY95+VZ[;:G<^(?\ @WK\+!BWAWXK_$#1VZK]I\JZ"_\
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MU@\A)CBD.WS"V,G:LT\N<=E-?;=_^QS^W"GAH6%I^T5X/CC@A\J&.+24MSM
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MS$GDUXE^RW\.?&'_  4'_P""BNI7_A;Q$?"OB'5=4O\ Q7'K+1-(=,*RM*C
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MVUI$TTK[2=B*"6.!R> >E>$R?\%/_@@H^7QF\GLNCWW]81116<YN.Q^O^%_
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9C<:U+&5I5&OYI.7YMD]%%%!P!1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
